Table 2. ET-1 production by cancer lines that cause bone metastases.
| Cell line | Bone metastases | ET-1, pg/ml per 105 cells per 48 h | [PTHrP], pM per 105 cells per 48 h |
|---|---|---|---|
| Breast cancers | |||
| ZR-75-1 | OB | 80.7 ± 5.2 | 0 |
| MCF-7 | OB | 18.9 ± 1.6 | 0 |
| T47D | OB | 227 ± 12.1 | 0 |
| BT483 | M | 22.3 ± 5.8 | 0 |
| MDA-MB-231 | OL | 0 | 0.54 ± 0.1 |
| BT549 | OL | 0 | 0.44 ± 0.12 |
| MDA-MB-435s | OL | 0 | 0.29 ± 0.12 |
| HS578T | N | 2.8 ± 2.1 | 0.46 ± 0.05 |
| MDA-MB-436 | N | 0 | 0.4 ± 0.4 |
| MDA-MB-361 | N | 0 | 0 |
| Prostate cancers | |||
| DU145 | N | 23.4 ± 1.5 | 0.75 ± 0.08 |
| LNCaP | N | 0 | 0.08 ± 0.08 |
| PC-3 | OL | 0 | 11.6 ± 0.82 |
OB, osteoblastic (with increased osteoid at tumor—bone interface); OL, osteolytic (with increased osteoclast numbers at tumor—bone interface); M, mixed (with regions of OB and OL in the same metastasis); N, none.